NASDAQ$HCAT
Health Catalyst Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Achieved strong performance, exceeded revenue and Adjusted EBITDA guidance, and raised full year 2022 revenue and Adjusted EBITDA guidance.
Health Catalyst reported strong Q3 2022 results, exceeding revenue and Adjusted EBITDA guidance. The company raised its full year 2022 revenue and Adjusted EBITDA guidance and expects the dollar-based retention achievement level to be between 97% and 101%.
- Total revenue for the quarter was $68.354 million, an 11% increase year-over-year.
- Technology revenue was $43.997 million, a 15% increase year-over-year.
- Professional services revenue was $24.357 million, a 4% increase year-over-year.
- Adjusted EBITDA was $(4.554) million, exceeding the mid-point of quarterly guidance.
Headline financials
Revenue & EPS history
Health Catalyst · Revenue · Quarterly
$68.4M
Revenue by segment
Health Catalyst · $68.4M total across 2 segments · Q3 2022
- Technology$44M+15.0%64.4%
- Professional Services$24.4M+3.8%35.6%
Forward guidance
For the fourth quarter of 2022, Health Catalyst expects total revenue between $66.9 million and $68.9 million, and Adjusted EBITDA between $(2.1) million and $(0.1) million. For the full year of 2022, the company expects total revenue between $274.0 million and $276.0 million, and Adjusted EBITDA between $(4.0) million and $(2.0) million.
Tailwinds
- Total revenue between $66.9 million and $68.9 million for Q4 2022
- Adjusted EBITDA between $(2.1) million and $(0.1) million for Q4 2022
- Total revenue between $274.0 million and $276.0 million for the full year 2022
- Adjusted EBITDA between $(4.0) million and $(2.0) million for the full year 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-3.1%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-4.0%
Avg return
30 days after
41%
11 / 27 earnings
Positive
+27.3%
Q2 2024
Best reaction
-36.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.9% | -21.7% | +4.6% | |
| Q4 2025 | -26.3% | -35.2% | -44.4% | |
| Q3 2025 | -5.6% | -20.5% | -10.2% | |
| Q1 2025 | +5.3% | +8.1% | +3.3% | |
| Q4 2024 | -11.1% | -8.5% | -7.9% | |
| Q3 2024 | +14.2% | +7.2% | +7.6% | |
| Q2 2024 | +27.3% | +7.3% | +22.9% | |
| Q1 2024 | -3.6% | +2.9% | -2.3% | |
| Q4 2023 | -14.7% | -8.9% | -14.4% | |
| Q3 2023 | +5.1% | -0.4% | +5.3% | |
| Q2 2023 | -8.0% | -5.0% | -12.4% | |
| Q1 2023 | -18.9% | -14.8% | -4.3% | |
| Q4 2022 | +7.3% | +5.8% | -14.8% | |
| Q3 2022 | +16.2% | +42.9% | +59.2% | |
| Q2 2022 | -36.6% | -34.7% | -35.9% | |
| Q1 2022 | -2.6% | +24.6% | +10.5% | |
| Q4 2021 | +1.5% | -7.1% | -3.7% | |
| Q3 2021 | -6.2% | -6.1% | -26.9% | |
| Q2 2021 | +1.5% | -2.3% | -2.8% | |
| Q1 2021 | -2.3% | -8.6% | -2.4% | |
| Q4 2020 | +0.6% | +0.1% | -2.1% | |
| Q3 2020 | -0.2% | -3.5% | +6.2% | |
| Q2 2020 | -7.2% | -10.9% | -3.4% | |
| Q1 2020 | -1.9% | -0.5% | -5.0% | |
| Q4 2019 | +1.3% | -5.8% | -20.1% | |
| Q3 2019 | +1.9% | -0.8% | -1.1% | |
| Q2 2019 | -11.5% | -7.8% | -13.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro